Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Autor: Ravaud, A, Motzer, Rj, Pandha, Hs, George, Dj, Pantuck, Aj, Patel, A, Chang, Yh, Escudier, B, Donskov, F, Magheli, A, Carteni, G, Laguerre, B, Tomczak, P, Breza, J, Gerletti, P, Lechuga, M1, Lin, X, Martini, Jf, Ramaswamy, K, Casey, M, Staehler, M, Patard, Jj, Gruenwald, V, Link, K, Doehn, C, Heinzer, H, Grimm, M-O, Wirth, M, Stoeckle, M, Heidenreich, A, Garcia del Muro Solans, X, Mellado, Bo, Castellano, Dg, Frydenberg, M, Schobinger, Sr, Dimopoulos, Ma, Rothermundt, C, Climent Duran MA, Melotti, B, Procopio, G, Boccardo, F, Sella, A, Stewart, S, Adenis, A, Jones, Rj, Chevreau, C, Prausova, J, Vyzula, R, Oudard, S, Jacqmin, D, Gravis, G, Varela, R, Herrmann, E, Lim, Hy, Lee, J-L, Kim, Yh, Kim, Jh, Y-C, Ou, Papakotoulas, P, Iacobelli, S, Chowdhury, S, Passalacqua, R, Tomasek, J, Anton Aparicio LM, Linassier, C, Hauser, S, Bergmann, L, Hawkins, Re, Szczylik, C, Zdrojowy, R, Sosnowski, M, Koralewski, P, Wiechnio, Pj, Schraml, J, Mardiak, J, Laurinc, P, Kliment, J, Rosenbaum, E, Lundstam, S, Flodgren, P, Ljungberg, B, Stenzl, A, Schnoeller, Tj, Mcdermott, Sr, Breathnach, Os, Mccaffrey, Ja, Donnellan, P, The, G-C, Rolland, F, Brekkan, E, Nilsson, C, Kim, Wy, Bishoff, J, Chung, J, Shore, Nd, Master, V, Tang Chen DY, Ye, D, Huang, Y, Jin, J, Song, B, Zhou, F, Galceran, Jc, Yao, X, Zhang, X.

Publikováno v: Ravaud, A, Motzer, R J, Pandha, H S, George, D J, Pantuck, A J, Patel, A, Chang, Y-H, Escudier, B, Donskov, F, Magheli, A, Carteni, G, Laguerre, B, Tomczak, P, Gerletti, P, Lechuga, M, Lin, X, Martini, J-F, Ramaswamy, K, Casey, M, Staehler, M, Patard, J-J & S-TRAC Investigators 2016, ' Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy ', The New England Journal of Medicine, vol. 375, no. 23, pp. 2246-2254 . https://doi.org/10.1056/NEJMoa1611406

BACKGROUNDSunitinib, a vascular endothelial growth factor pathway inhibitor, is an effectivetreatment for metastatic renal-cell carcinoma. We sought to determine the efficacyand safety of sunitinib in patients with locoregional renal-cell carcinoma a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044148e0163ba78bfbd9d2be3de578c8
https://surrey.eprints-hosting.org/812586/